Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 762,656 shares of RXRX, which is worth approximately $4.88 Million. The most recent transaction as insider was on Oct 06, 2022, when has been sold 18,500 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 763K

0.52% 3M change

8.86% 12M change

Total Value Held $4.88 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 06 2022	BUY Conversion of derivative security	-	18,500 Added 3.08%	581,459 Class A Common Stock
Sep 19 2022	SELL Bona fide gift	-	3,000 Reduced 0.56%	534,805 Class A Common Stock
Sep 01 2022	SELL Open market or private sale	$378,092 $10.34 p/Share	36,566 Reduced 6.24%	549,262 Class A Common Stock
Sep 01 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 5.22%	567,328 Class A Common Stock
Sep 01 2022	BUY Conversion of derivative security	-	18,500 Added 3.16%	567,762 Class A Common Stock
Aug 17 2022	SELL Bona fide gift	-	3,000 Reduced 0.55%	537,805 Class A Common Stock
Aug 15 2022	SELL Payment of exercise price or tax liability	$74,533 $12.96 p/Share	5,751 Reduced 1.06%	536,078 Class A Common Stock
Aug 04 2022	SELL Open market or private sale	$349,469 $9.49 p/Share	36,825 Reduced 6.36%	541,829 Class A Common Stock
Aug 04 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 5.28%	560,154 Class A Common Stock
Aug 04 2022	BUY Conversion of derivative security	-	18,500 Added 3.2%	560,329 Class A Common Stock
Jul 19 2022	SELL Bona fide gift	-	3,000 Reduced 0.55%	540,805 Class A Common Stock
Jul 07 2022	SELL Open market or private sale	$336,253 $9.06 p/Share	37,114 Reduced 6.56%	528,904 Class A Common Stock
Jul 07 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 5.4%	547,518 Class A Common Stock
Jul 07 2022	BUY Conversion of derivative security	-	18,500 Added 3.27%	547,404 Class A Common Stock
Jun 21 2022	SELL Bona fide gift	-	3,000 Reduced 0.55%	543,805 Class A Common Stock
Jun 02 2022	SELL Open market or private sale	$242,506 $6.11 p/Share	39,690 Reduced 7.14%	516,268 Class A Common Stock
Jun 02 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 5.49%	537,458 Class A Common Stock
Jun 02 2022	BUY Conversion of derivative security	-	18,500 Added 3.34%	534,768 Class A Common Stock
May 19 2022	SELL Bona fide gift	-	12,000 Reduced 2.15%	546,805 Class A Common Stock
May 16 2022	SELL Payment of exercise price or tax liability	$32,682 $5.67 p/Share	5,764 Reduced 1.13%	506,208 Class A Common Stock
May 12 2022	SELL Bona fide gift	-	12,000 Reduced 2.1%	558,805 Class A Common Stock
May 05 2022	SELL Open market or private sale	$119,140 $6.44 p/Share	18,500 Reduced 3.49%	511,972 Class A Common Stock
May 05 2022	BUY Conversion of derivative security	-	18,500 Added 3.37%	530,472 Class A Common Stock
May 04 2022	SELL Open market or private sale	$206,577 $6.49 p/Share	31,830 Reduced 5.85%	511,972 Class A Common Stock
May 04 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 5.61%	525,302 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account